MOONRAY-01, a Phase 1 Study of LY3962673, a Potent, Orally Bioavailable, and Selective KRAS G12D Inhibitor in KRAS G12D -Mutant Solid Tumors.
Journal of Clinical Oncology(2025)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined